Safety and efficacy of synthetic antitumor antibodies
The surface of many malignant cells expresses a protein that disrupts the ability of cells of the immune system to destroy them. This protein, known as programmed cell death ligand-1 (PD-L1), interacts with the corresponding receptor on the surface of T-lymphocytes (PD-1), depriving them of the ability to destroy tumor cells.
MPDL3280A monoclonal antibodies developed by Genentech specialists selectively bind to PD-L1 and block its activity.
As part of a clinical study, 30 patients with various types of locally progressive or metastatic solid tumors received intravenous injection of MPDL3280A antibodies once every three weeks. The dose of the drug was gradually increased from 0.01 to 20 mg / kg of the patient's body weight. At the same time, no manifestations of dose-limiting toxicity and adverse reactions of the 4th degree of severity were registered in patients.
Moreover, the researchers claim, from a therapeutic point of view, already at this stage they managed to achieve a response to treatment in a sufficiently large number of patients with a wide range of diseases, including lung, kidney, colon and stomach cancers.
They also note that the experimental MPDL3280A antibodies do not block the activity of the programmed death-2 (PD-L2) ligand expressed by cells of normal tissues and interacting with the same T-lymphocyte surface receptor.
The results of the study were presented at the annual congress of the American Association for Cancer Research, held on April 6-10, 2013 in Washington.
Portal "Eternal youth" http://vechnayamolodost.ru based on the materials of the American Association for Cancer Research
via Newswise: Engineered Antibody Demonstrated Safety, Efficacy in Wide Range of Advanced Tumors.